Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations

By: via Benzinga
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.